Inhibikase Therapeutics (IKT) Stock Price, Quote, News & History

Comments

Inhibikase Therapeutics Inc (IKT) Stock Price, Quote, News & History

IKTNASDAQ

Trade with Public

$1.79

-0.01-0.56%

At close: Apr 6, 5:00 PM EST

$1.79

N/A

After Hours: 4:40 PM EST

OverviewNews Earnings Analyst Ratings Insider Trades Short Interest Stock Report

Key Statistics

Open

$1.78

Close

$1.79

Volume / Avg.

692.79K / 1.81M

Day Range

$1.75 - $1.83

52 Wk Range

1.33 - 2.37

Market Cap

$236.34M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

50

Short Interest

21.29%

Days to Cover

11.91

Recent Inhibikase Therapeutics Inc News

This Cytokinetics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday

Avi Kapoor

Why Tesla Shares Are Trading Higher By Around 11%; Here Are 20 Stocks Moving Premarket

Avi Kapoor

Dow Surges 350 Points; US Crude Oil Stocks Increase

Avi Kapoor

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-27.79M

Investing Cash Flow (TTM)

2.05M

Financing Cash Flow (TTM)

108.46M

Free Cash Flow (TTM)

-28.24M

Capital Expenditure (TTM)

-452.02K

Net Change in Cash (TTM)

82.73M

Analyst Trends and Forecast

3

Dec 25

1

Jan

1

Mar

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.1

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$150.03M

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

-

PB Ratio (TTM)

1.37

Earnings Yield % (TTM)

-27.22%

Earnings Yield % (FWD)

-29.17%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

$1.31

Company Debt

Total Debt

-

LT Debt

-

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-

Total Cash

$139.22M

Debt to Equity

0.00

Issuance of Debt (TTM)

-

Repayment of Debt (TTM)

-

Key Statistics

Open

$1.78

Close

$1.79

Volume / Avg.

692.79K / 1.81M

Day Range

$1.75 - $1.83

52 Wk Range

1.33 - 2.37

Market Cap

$236.34M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

50

Short Interest

21.29%

Days to Cover

11.91

About

Sector

Health Care

Industry

Biotechnology

Inhibikase Therapeutics Inc a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases, namely, Pulmonary Arterial Hypertension (PAH), in which aberrant signaling through type III receptor tyrosin...

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

Q

How do I buy Inhibikase Therapeutics (IKT) stock?

A

You can purchase shares of Inhibikase Therapeutics (NASDAQ:IKT) through any online brokerage.

View our list of the best stock brokerages

Q

Who are Inhibikase Therapeutics (IKT) competitors?

A

Other companies in Inhibikase Therapeutics’s space includes: Atrium Therapeutics Inc (NASDAQ:RNA), Voyager Therapeutics Inc (NASDAQ:VYGR), Korro Bio Inc (NASDAQ:KRRO), Eledon Pharmaceuticals Inc (NASDAQ:ELDN) and Anika Therapeutics Inc (NASDAQ:ANIK).

Q

What is the forecast, or price target, for Inhibikase Therapeutics (IKT) stock?

A

Inhibikase Therapeutics has a consensus price target of $5.50.

Q

What is the current price for Inhibikase Therapeutics (IKT)?

A

The stock price for Inhibikase Therapeutics (NASDAQ: IKT) is $1.79 last updated April 6, 2026 at 4:40 PM EDT.

Q

Does Inhibikase Therapeutics (IKT) pay a dividend?

A

There are no upcoming dividends for Inhibikase Therapeutics.

Q

When is Inhibikase Therapeutics (NASDAQ:IKT) reporting earnings?

A

Inhibikase Therapeutics does not have any upcoming earnings scheduled.

Q

Is Inhibikase Therapeutics (IKT) going to split?

A

There is no upcoming split for Inhibikase Therapeutics.

Q

What sector and industry does Inhibikase Therapeutics (IKT) operate in?

A

Inhibikase Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

People Also Watch

Atrium Therapeutics Inc

NASDAQ:RNA

$13.67

%

Voyager Therapeutics Inc

Eledon Pharmaceuticals Inc

NASDAQ:ELDN

$3.19

3.24%

Anika Therapeutics Inc

Fennec Pharmaceuticals Inc

NASDAQ:FENC

$6.45

0.47%

Key Statistics

Open

$1.78

Close

$1.79

Volume / Avg.

692.79K / 1.81M

Day Range

$1.75 - $1.83

52 Wk Range

1.33 - 2.37

Market Cap

$236.34M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

50

Short Interest

21.29%

Days to Cover

11.91

Recent Inhibikase Therapeutics Inc News

This Cytokinetics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday

Avi Kapoor

Why Tesla Shares Are Trading Higher By Around 11%; Here Are 20 Stocks Moving Premarket

Avi Kapoor

Dow Surges 350 Points; US Crude Oil Stocks Increase

Avi Kapoor

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-27.79M

Investing Cash Flow (TTM)

2.05M

Financing Cash Flow (TTM)

108.46M

Free Cash Flow (TTM)

-28.24M

Capital Expenditure (TTM)

-452.02K

Net Change in Cash (TTM)

82.73M

Analyst Trends and Forecast

3

Dec 25

1

Jan

1

Mar

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.1

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$150.03M

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

-

PB Ratio (TTM)

1.37

Earnings Yield % (TTM)

-27.22%

Earnings Yield % (FWD)

-29.17%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

$1.31

Company Debt

Total Debt

-

LT Debt

-

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-

Total Cash

$139.22M

Debt to Equity

0.00

Issuance of Debt (TTM)

-

Repayment of Debt (TTM)

-

Key Statistics

Open

$1.78

Close

$1.79

Volume / Avg.

692.79K / 1.81M

Day Range

$1.75 - $1.83

52 Wk Range

1.33 - 2.37

Market Cap

$236.34M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

50

Short Interest

21.29%

Days to Cover

11.91

About

Sector

Health Care

Industry

Biotechnology

Inhibikase Therapeutics Inc a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases, namely, Pulmonary Arterial Hypertension (PAH), in which aberrant signaling through type III receptor tyrosin...

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry